<?xml version="1.0" encoding="utf-8" ?>
<feed xmlns="http://www.w3.org/2005/Atom">
<title>Anicecommunication - Latest News</title>
<link href="https://news.prfree.org/rss/anicecommunication/latest.xml"></link>
<updated>2026-07-20T11:49:53+00:00</updated>
<id>urn:uuid:c9fd4689-30c4-c3bf-a4e4-16e026c74e44</id>
<entry>
<title>EMN26 study on Iberdomide reported substantial response improvements in over 50% of Multiple Myeloma treated patients</title>
<link href="https://news.prfree.org/@anicecommunication/emn26-study-on-iberdomide-reported-substantial-response-improvements-in-over-50-of-multiple-myeloma-treated-patients-7fcikg4cw1ra"></link>
<id>urn:uuid:39237352-6780-1718-4d0f-773cecab758e</id>
<summary type="html"><![CDATA[Iberdomide maintenance therapy after transplantation in Newly Diagnosed Multiple Myeloma showed a favourable safety profile and induced superior response improvement as compared with Lenalidomide. Study underway in Netherlands, Italy, France, Greece]]></summary>
<updated>2024-02-16T16:28:59+00:00</updated>
</entry>
</feed>